---
figid: PMC6589502__fig-2
figtitle: 'Generalized Lymphatic Anomaly and Gorham–Stout Disease: Overview and Recent
  Insights'
organisms:
- NA
pmcid: PMC6589502
filename: fig-2.jpg
figlink: /pmc/articles/PMC6589502/figure/f2/
number: F2
caption: Mutations and signaling pathways involved in LMs. Mutations in EPHB4 and
  NRAS lead to activate the signaling of RAS/MEK/ERK pathway. Mutations in PIK3CA
  and AKT lead to activate the signaling of PIK3/AKT/mTOR pathway. CLOVES, congenital
  lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal
  and spinal; EFNB2, ephrin-B2; EPHB4, ephrin B4; GLA, generalized lymphatic anomaly;
  LM, lymphatic malformation; mTOR, mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate
  3-kinase catalytic subunit alpha; PROS, PIK3CA-related overgrowth spectrum; RTK,
  receptor tyrosine kinase; VEGF-C, vascular endothelial growth factor-C; VEGFR, VEGF
  receptor.
papertitle: 'Generalized Lymphatic Anomaly and Gorham–Stout Disease: Overview and
  Recent Insights.'
reftext: Michio Ozeki, et al. Adv Wound Care (New Rochelle). 2019 Jun 1;8(6):230-245.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9642649
figid_alias: PMC6589502__F2
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC6589502__F2
ndex: b22582ac-deb9-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6589502__fig-2.html
  '@type': Dataset
  description: Mutations and signaling pathways involved in LMs. Mutations in EPHB4
    and NRAS lead to activate the signaling of RAS/MEK/ERK pathway. Mutations in PIK3CA
    and AKT lead to activate the signaling of PIK3/AKT/mTOR pathway. CLOVES, congenital
    lipomatous overgrowth, vascular malformations, epidermal nevi, scoliosis/skeletal
    and spinal; EFNB2, ephrin-B2; EPHB4, ephrin B4; GLA, generalized lymphatic anomaly;
    LM, lymphatic malformation; mTOR, mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate
    3-kinase catalytic subunit alpha; PROS, PIK3CA-related overgrowth spectrum; RTK,
    receptor tyrosine kinase; VEGF-C, vascular endothelial growth factor-C; VEGFR,
    VEGF receptor.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ras
  - Ras64B
  - Ras85D
  - MKP-4
  - p38b
  - rl
  - Tie
  - InR
  - wg
  - gl
  - syndrome
  - pros
  - lm
  - Raf
  - Akt
  - Dsor1
  - Mtk
  - Mtor
  - Tor
  - Erk7
  - pi
  - EFNB2
  - VEGFC
  - FLT4
  - EPHB4
  - PIK3CG
  - KRAS
  - HRAS
  - NRAS
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - PIK3CA
  - GLA
  - NAT8
  - PROS1
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - AKT1
  - AKT2
  - AKT3
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - MTOR
  - EPHB2
  - Pazopanib
  - ETrametinib
  - Sirolimus
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
